Honouring Dr. David Osoba
Published:Category:
With sorrow, CCTG would like to note the recent passing of Dr. David Osoba.
Read More2020 a Year in Review
Published:Category: Office of the Director
A look back at 2020, a pandemic year that saw tremendous achievements across the CCTG network
This past year has been one of constant challenge within our group, network, country, and the world. Yet despite the disruptions to our daily lives and work, this year has also been one of immense accomplishment.
Read MoreTrial Activation: PR21
Published:Category: Trials
PR21 A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has been centrally activated.
Read More2020 Holiday Hours - CCTG TTDR & BARL
Published:Category: Group updates
Holiday hours and days of operation for the CCTG central office, CCTG’s Tumour Tissue Data Repository and the Bay Area Research Logistics.
Read MoreDr. Joseph Connors appointed to the Order of Canada
Published:Category: News
Everyone at CCTG would like to congratulate Dr Joseph Connors for his recent appointment to the Order of Canada, as one of 114 Canadian appointees “whose service has shaped our society; whose innovations ignite our imaginations; and whose compassion unites our communities.”
Read MoreCCTG posters at ASH Annual Meeting and Exposition
Published:Category: Publications
As with most events in 2020 the 62nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in.
Read MoreMAC15 RxPONDER trial presented at SABCS
Published:Category: Publications
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.
Read MoreClosed to Accrual: MAC21
Published:Category: Trials
MAC21 (NCT02927249), A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, has closed to accrual after completion of target accrual.
Read More